Can Symbicort Lead to Osteoporosis?
Yes, Symbicort (budesonide/formoterol) can contribute to decreased bone mineral density and potentially increase osteoporosis risk, particularly with long-term use, though the risk is lower than with systemic corticosteroids.
Understanding the Risk
The budesonide component of Symbicort is an inhaled corticosteroid (ICS) that, despite being designed for local lung delivery, does achieve systemic absorption and can affect bone metabolism 1. The FDA label explicitly warns that decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids 1.
Key Evidence from Clinical Studies
A 52-week study in COPD patients using Symbicort showed reassuring findings: mean changes in BMD were small (ranging from -0.01 to 0.01 g/cm²), and BMD remained stable over the entire treatment period for both total hip and spine regions 1. More recent research in 456 COPD patients confirmed that changes from baseline in lumbar spine BMD over 52 weeks were minimal (least squares mean range -0.12 to 0.38%) and not clinically meaningful 2.
However, a broader review found that inhaled corticosteroids cause a dose-related reduction in bone mineral density, with three cross-sectional studies demonstrating a dose-related increase in fractures compared to controls 3.
Risk Stratification and Monitoring
Patients at highest risk include those with:
- Prolonged immobilization
- Family history of osteoporosis
- Postmenopausal status
- Tobacco use
- Advanced age
- Poor nutrition
- Chronic use of other bone-depleting drugs (anticonvulsants, oral corticosteroids)
Monitoring Recommendations
The FDA label strongly recommends:
- Assess BMD prior to initiating Symbicort in high-risk patients
- Monitor BMD periodically during treatment
- If significant BMD reductions occur and Symbicort remains medically necessary, strongly consider medications to treat or prevent osteoporosis
Comparison with Other Corticosteroid Formulations
An important distinction: budesonide (whether inhaled or oral controlled-release) appears to have less impact on bone than systemic prednisolone. In Crohn's disease patients, those switching from prednisolone to budesonide showed improvement in bone density 4. Guidelines for inflammatory bowel disease specifically recommend that "the dose of glucocorticoids should be kept to a minimum and, where possible, non-systemic formulations or controlled release budesonide advised" 5.
Research in corticosteroid-naive Crohn's patients demonstrated that budesonide caused smaller reductions in BMD than prednisolone (mean -1.04% vs -3.84%; P = .0084) 4.
Clinical Management Strategy
For patients requiring Symbicort:
Initial Assessment:
- Evaluate all osteoporosis risk factors before starting therapy
- Obtain baseline BMD in high-risk patients
- Consider DEXA scan with vertebral fracture assessment
Preventive Measures:
- Ensure adequate calcium intake (1,000-1,200 mg/day)
- Vitamin D supplementation (600-800 IU/day, targeting serum level ≥20 ng/ml)
- Weight-bearing exercise
- Smoking cessation
- Limit alcohol to 1-2 drinks/day
Pharmacologic Intervention:
Ongoing Monitoring:
- Reassess BMD periodically (timing based on individual risk)
- Monitor for height loss or new back pain (vertebral fractures)
- Regular ophthalmologic exams (ICS can also increase cataract/glaucoma risk)
Important Caveats
The absolute risk of clinically significant bone loss or fracture in most Symbicort users is relatively low, especially compared to systemic corticosteroids. The 12-month COPD study showed that changes in posterior subcapsular cataract scores and BMD were similar across treatment groups, including the non-ICS formoterol-only group 1.
Do not discontinue necessary asthma or COPD therapy due to bone concerns alone—uncontrolled respiratory disease carries its own significant morbidity and mortality risks. Instead, implement bone-protective strategies while continuing effective respiratory management.
The risk appears dose-dependent, so using the lowest effective dose of Symbicort that controls symptoms is prudent 1, 3.